On Tuesday, Shares of Netlist Inc. (NASDAQ:NLST), surged 25.74% to $0.63.
Netlist, declared that it has reached a Letter of Intent with LG Electronics, Inc. (LG) to jointly work on a HyperVault Mobile Memory Controller (HVMMC) with the intention of adopting HVMMC on a next generation mobile system of LG Electronics.
Under the LOI, it is predictable that Netlist and LG would combine the strengths of both companies to actively cooperate to build a superior mobile memory controller for smart phones. The new HVMMC would benefit the end user by allowing a mobile system to reduce DRAM density, and therefore lower costs, without loss of system performance. The worldwide shipment of smartphones is anticipated to reach 1.9 billion units by 2018 according to forecasts by CCS Insight. It is predictable that a growing share of those units will use a minimum of 3GB of DRAM or above.
Netlist, Inc. designs, manufactures, and sells a range of logic-based memory subsystems for the datacenter, storage, and high-performance computing markets worldwide. Its memory subsystems comprise of combinations of dynamic random access memory integrated circuits, NAND flash memory components, application-specific integrated circuits, and other components assembled on printed circuit boards.
At the end of Tuesday’s trade, Shares of TAL Education Group (NYSE:XRS), jumped 6.22% to $38.25, hitting its highest level.
TAL Education Group, declared its unaudited financial results for the fourth quarter and the fiscal year ended February 28, 2015.
Highlights for the Fourth Quarter of Fiscal Year 2015
- Net revenues raised by 41.6% year-over-year to US$123.2 million from US$87.0 million in the same period of the preceding year.
- Income from operations raised by 3.2% to US$14.9 million, from US$14.4 million in the same period of the preceding year.
- Non-GAAP income from operations raised by 18.8% to US$20.2 million, from US$17.0 million in the same period of the preceding year.
- Net income attributable to TAL reduced by 17.8% year-over-year to US$13.7 million from US$16.7 million in the same period of the preceding year, taking into account the exchange losses of US$2.8 million.
- Non-GAAP net income attributable to TAL, which excluded share-based compensation expenses, reduced by 1.3% year-over-year to US$19.0 million from US$19.3 million in the same period of the preceding year, taking into account the exchange losses of US$2.8 million.
- Basic and diluted net income per American Depositary Share (“ADS”) were both US$0.17. Non-GAAP basic and diluted net income per ADS, which excluded share-based compensation expenses, were US$0.24 and US$0.23, respectively. Each ADS represents two Class A common shares.
- Cash, cash equivalents and term deposits totaled US$491.4 million as of February 28, 2015, contrast to US$269.9 million as of February 28, 2014.
- Total student enrollments raised by 44.4% year-over-year to about 502,350 from about 348,000 in the same period of the preceding year.
- Total physical network comprised of 289 learning centers as of February 28, 2015, unchanged from 289 as of November 30, 2014.
TAL Education Group, together with its auxiliaries, provides K-12 after-school tutoring services under the Xueersi brand name in China. It offers tutoring services to K-12 students covering various academic subjects, counting mathematics, physics, chemistry, biology, history, geography, political science, English, Chinese, and others.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), ended its last trade with 5.97% gain, and closed at $3.55.
Catalyst Pharmaceutical Partners, declared that Shin Oh, MD, one of its clinical investigators, will be making an oral presentation of safety and efficacy data from the Firdapse(R) Phase 3 clinical trial in patients with Lambert-Eaton myasthenic syndrome (LEMS) at the American Academy of Neurology (AAN) 67th Annual Meeting. The AAN meeting will be held April 18 to 25, 2015, in Washington, DC.
The oral presentation titled, “Amifampridine phosphate (Firdapse(R)) is safe and effective in a pivotal Phase 3 trial in LEMS patients” will be given during the Clinical Trials Plenary Session on Friday, April 24, 12:00 pm-1:30 pm. This session was designed by the AAN to address important clinical topics identified throughout the neurology community that affect patient care, and the Science Committee considered the Firdapse(R)Trial results an advancement in the field of autoimmune disease and neuroscience.
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
Finally, Wabash National Corp. (NYSE:WNC), closed at $14.66, with 5.16% gain.
Wabash National, declared a new five-year agreement with Aurora Parts & Accessories, LLC to be the exclusive supplier of all aftermarket parts for the company’s dry van, refrigerated van, and platform trailers sold under the leading brand names Wabash National, Transcraft and Benson.
After careful consideration and a comprehensive evaluation of all options accessible, Wabash National selected Aurora as providing the best value to Wabash, Transcraft and Benson customers.
With the new agreement, Wabash National and Aurora will collaborate in the day-to-day and planned administration of providing aftermarket parts to Wabash National, Transcraft and Benson dealers and customers.
“We are excited to continue our relationship with Wabash as their exclusive provider of aftermarket parts,” said Mike Conley, vice president of sales at Aurora. “Wabash and Aurora share a long legacy of leadership through innovation. This common culture supports a mutual commitment to premium quality products and service. We look forward to many joint initiatives to further enhance the overall customer experience.”
Wabash National Corporation designs, manufactures, and markets truck and tank trailers, intermodal equipment, and transportation related products in North America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
